Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q9NQW7

UPID:
XPP1_HUMAN

ALTERNATIVE NAMES:
Aminoacylproline aminopeptidase; Cytosolic aminopeptidase P; Soluble aminopeptidase P; X-Pro aminopeptidase 1; X-prolyl aminopeptidase 1, soluble

ALTERNATIVE UPACC:
Q9NQW7; A8K071; G5E9Y2; G8JLB2; O15250; Q53EX6; Q8N3Q0; Q96D23

BACKGROUND:
Xaa-Pro aminopeptidase 1, recognized by its alternative names such as Cytosolic aminopeptidase P and Soluble aminopeptidase P, is pivotal in the N-terminal processing of peptides. It specifically targets and removes prolyl residues, contributing significantly to cellular peptide turnover and homeostasis.

THERAPEUTIC SIGNIFICANCE:
The exploration of Xaa-Pro aminopeptidase 1's function offers promising avenues for therapeutic intervention. Given its critical role in peptide processing, targeting this enzyme could lead to innovative treatments for diseases linked to peptide metabolism and homeostasis.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.